VOLTAIRE-X: Pharmacokinetics, Safety, Immunogenicity and Efficacy of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: a Randomized, Double-blind, Parallel-arm, Multiple-dose, Active Comparator Trial

Trial Profile

VOLTAIRE-X: Pharmacokinetics, Safety, Immunogenicity and Efficacy of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: a Randomized, Double-blind, Parallel-arm, Multiple-dose, Active Comparator Trial

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics; Registrational
  • Acronyms VOLTAIRE-X
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 24 Jul 2018 Planned End Date changed from 19 Jul 2019 to 15 Jul 2020.
    • 24 Jul 2018 Planned primary completion date changed from 28 Feb 2019 to 12 Mar 2020.
    • 27 Jul 2017 According to a Boehringer Ingelheim media release, the first patient has been enrolled in this trial and the results from the trial are expected in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top